We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+42.24%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$431M
AUM Growth
+$40.6M
Cap. Flow
-$22.4M
Cap. Flow %
-5.2%
Top 10 Hldgs %
39.17%
Holding
104
New
21
Increased
36
Reduced
26
Closed
21

Top Buys

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$12.5M
2
AMGN icon
Amgen
AMGN
+$10.8M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$4.35M
4
DHR icon
Danaher
DHR
+$3.96M
5
FOCL
EDAP TMS S.A.
FOCL
+$3.61M

Top Sells

Rank Stock Value
1
VCEL icon
Vericel Corp
VCEL
+$13.2M
2
SDGR icon
Schrodinger
SDGR
+$10.4M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$9.41M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$9.05M
5
GNMK
GenMark Diagnostics, Inc
GNMK
+$9.02M

Sector Composition

Rank Sector Weight
1 Healthcare 92.25%
2 Technology 1.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACRS icon
1
Aclaris Therapeutics
ACRS
$869M
$43.1M 10%
1,709,136
-166,200
-9% -$3.25M
QQQ icon
2
PUT
Invesco QQQ Trust
QQQ
$484B
$16M 3.7%
+50,000
New +$16M
DHR icon
3
Danaher
DHR
$144B
$14.6M 3.39%
73,303
+19,512
+36% +$3.96M
CRL icon
4
Charles River Laboratories
CRL
$12.8B
$14.5M 3.36%
50,000
+10,334
+26% +$2.87M
NTRA icon
5
Natera
NTRA
$46.4B
$14.2M 3.3%
139,893
+19,026
+16% +$2.08M
HUM icon
6
Humana
HUM
$46.2B
$13.8M 3.21%
33,000
+8,192
+33% +$3.27M
ICAD
7
DELISTED
iCAD Inc
ICAD
$13.8M 3.19%
648,131
+105,529
+19% +$1.78M
DXCM icon
8
DexCom
DXCM
$32B
$13.6M 3.15%
150,872
-15,240
-9% -$1.43M
IQV icon
9
IQVIA
IQV
$39.3B
$12.8M 2.96%
66,048
+7,824
+13% +$1.47M
UTHR icon
10
United Therapeutics
UTHR
$23.1B
$12.5M 2.91%
+74,874
New +$12.5M
CDMO
11
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$12.3M 2.86%
675,000
-74,511
-10% -$1.24M
AMGN icon
12
Amgen
AMGN
$222B
$11.2M 2.6%
+45,059
New +$10.8M
ALNY icon
13
Alnylam Pharmaceuticals
ALNY
$29.3B
$9.18M 2.13%
65,043
+28,882
+80% +$4.35M
RCUS icon
14
Arcus Biosciences
RCUS
$3.64B
$8.87M 2.06%
315,882
+84,124
+36% +$2.93M
XLRN
15
DELISTED
Acceleron Pharma
XLRN
$8.51M 1.98%
62,780
+10,322
+20% +$1.33M
CTLT
16
DELISTED
CATALENT, INC.
CTLT
$8.38M 1.94%
79,526
-4,593
-5% -$512K
PODD icon
17
Insulet
PODD
$9.79B
$8.13M 1.89%
31,169
+582
+2% +$156K
ITMR
18
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
$8.06M 1.87%
336,429
+54,102
+19% +$1.29M
DRNA
19
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$7.75M 1.8%
303,268
-28,245
-9% -$721K
AVTR icon
20
Avantor
AVTR
$9.19B
$7.29M 1.69%
252,163
+101,291
+67% +$2.92M
XENE icon
21
Xenon Pharmaceuticals
XENE
$6.12B
$6.7M 1.56%
374,395
+12,706
+4% +$215K
ONCT
22
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$6.48M 1.5%
38,939
+20,100
+107% +$2.66M
IMUX icon
23
Immunic
IMUX
$195M
$6.39M 1.48%
40,122
+3,453
+9% +$586K
HZNP
24
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$6.3M 1.46%
68,430
-107,282
-61% -$9.05M
VCEL icon
25
Vericel Corp
VCEL
$2.31B
$6.11M 1.42%
110,000
-290,743
-73% -$13.2M
1
2 3 4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
SFO
Stokes Family Office New Orleans, Louisiana $969M AUM 19.6% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return

Parkman Healthcare Partners's Q1 2021 Portfolio in Review

As of Q1 2021, Parkman Healthcare Partners held 104 positions worth $431M, up 10% from $390M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Parkman Healthcare Partners withdrew a net $22.4M in Q1 2021, closing 21 positions and reducing 26 holdings. Its most notable exit was GW Pharmaceuticals Plc American Depositary Shares, an estimated $9.41M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 92% a quarter earlier, followed by Technology.

Against the trend, Parkman Healthcare Partners opened a new position in United Therapeutics worth $12.5M.

  • Parkman Healthcare Partners's largest Q1 2021 buy was United Therapeutics: 74,874 shares worth $12.5M.
  • Parkman Healthcare Partners added most to Alnylam Pharmaceuticals in Q1 2021, an estimated $4.35M increase.
  • Parkman Healthcare Partners's biggest Q1 2021 reduction was Vericel Corp, cutting an estimated $13.2M.
  • Parkman Healthcare Partners fully exited GW Pharmaceuticals Plc American Depositary Shares in Q1 2021, selling an estimated $9.41M.
  • Parkman Healthcare Partners's ten largest holdings make up 39% of its $431M portfolio in Q1 2021.
  • Parkman Healthcare Partners opened 21 new positions and closed 21 in Q1 2021.
  • Parkman Healthcare Partners's portfolio value rose 10% quarter-over-quarter to $431M.

Based on Parkman Healthcare Partners's 13F filing for Q1 2021, filed 14 May 2021.